African Journal of Biochemistry Research
Subscribe to AJBR
Full Name*
Email Address*

Article Number - 85B096E65668


Vol.11(8), pp. 43-48 , August 2017
DOI: 10.5897/AJBR2017.0939
ISSN: 1996-0778



Full Length Research Paper

Haptoglobin polymorphism and cardiovascular risk factors in followed epileptic patients at Fann National University Hospital



Papa Madieye GUEYE
  • Papa Madieye GUEYE
  • Laboratory of Pharmaceutical Biochemistry, Faculty of Medicine, Pharmacy, University Cheikh Anta DIOP, Dakar, Senegal.
  • Google Scholar
Moustapha DJITE
  • Moustapha DJITE
  • Laboratory of Biochemistry, University Hospital Fann, Dakar, Senegal.
  • Google Scholar
El Hadji Malick NDOUR
  • El Hadji Malick NDOUR
  • Laboratory of Pharmaceutical Biochemistry, Faculty of Medicine, Pharmacy, University Cheikh Anta DIOP, Dakar, Senegal.
  • Google Scholar
Fatou GUEYE-TALL
  • Fatou GUEYE-TALL
  • Laboratory of Biochemistry, University Hospital Fann, Dakar, Senegal.
  • Google Scholar
Nene Oumou Kesso BARRY
  • Nene Oumou Kesso BARRY
  • Laboratory of Biochemistry, University Hospital Fann, Dakar, Senegal.
  • Google Scholar
Aissatou SARR
  • Aissatou SARR
  • Laboratory of Biochemistry, University Hospital Fann, Dakar, Senegal.
  • Google Scholar
Rokhaya NDIAYE DIALLO
  • Rokhaya NDIAYE DIALLO
  • Laboratory of Pharmaceutical Biochemistry, Faculty of Medicine, Pharmacy, University Cheikh Anta DIOP, Dakar, Senegal.
  • Google Scholar
Philomène LOPEZ SALL
  • Philomène LOPEZ SALL
  • Laboratory of Pharmaceutical Biochemistry, Faculty of Medicine, Pharmacy, University Cheikh Anta DIOP, Dakar, Senegal.
  • Google Scholar
Aynina CISSE
  • Aynina CISSE
  • Laboratory of Pharmaceutical Biochemistry, Faculty of Medicine, Pharmacy, University Cheikh Anta DIOP, Dakar, Senegal.
  • Google Scholar
Pape Amadou DIOP
  • Pape Amadou DIOP
  • Laboratory of Pharmaceutical Biochemistry, Faculty of Medicine, Pharmacy, University Cheikh Anta DIOP, Dakar, Senegal.
  • Google Scholar







 Received: 19 March 2017  Accepted: 12 July 2017  Published: 31 August 2017

Copyright © 2017 Author(s) retain the copyright of this article.
This article is published under the terms of the Creative Commons Attribution License 4.0


The aim of our research was to evaluate the cardiovascular risk factors on epileptic patients treated at the Fann University Hospital and to study the influence of haptoglobin (Hp) polymorphism on disease progression. In order to do that, eighty-six (86) patients followed in neurology for at least 2 years were recruited. Each patient was matched to a control according to age and sex. Hp phenotyping was performed by electrophoresis on polyacrylamide gel, and lipid peroxidation was quantified by the dosage of the thiobarbituric acid reacting substances (TBARS). The determination of a number of biochemical parameters was performed in both patients and controls. The evaluation of lipid parameters showed significant differences in total cholesterol levels, triglycerides, low-density lipoprotein (LDL) cholesterol and atherogenic index between patients and controls. For C-Reactive Protein-ultra sensible (CRP-us) values greater than 3 mg / L, a statistically significant difference was found (p = 0.009). The frequencies of the three major phenotypes of patients compared to controls has shown significant difference only for Hp2-2 phenotype (p = 0.042). The significant increase of TBARS for patients compared to controls suggested an oxidative mechanism. Results have shown a risk of developing cardiovascular diseases during the progression of epilepsy. The influence of Hp polymorphism in modulating oxidative stress suggests that taking antioxidants may have a beneficial effect, especially in patients of phenotype Hp2-2.

Key words: Epilepsy, haptoglobin polymorphism, cardiovascular risks.

Aaberg KM, Bakken IJ, Lossius MI, Lund-Søraas C, Håberg SE, Stoltenberg C, Suren P, Chin R (2016). Comorbidity and Childhood Epilepsy: A Nationwide Registry Study. Pediatrics 138(3): pii:e20160921.
Crossref

 

Al-Balaghee S, Al-Balaghee Z, Shabani A, Ghadam P, Bandehpour M, Askari Mehr A, Kazemi B (2015). Determination of haptoglobin genotype in an Iranian population with idiopathic generalized epilepsy. Rep. Biochem. Mol. Biol. 3(2):51-55.

 

Anderson GD, Temkin NR, Dikmen SS, Diaz-Arrastia R, Machamer JE, Farhrenbruch C, Miller JW, Sadrzadeh SMH (2009). Haptoglobin Phenotype and Apolipoprotein E Polymorphism: Relationship to Post-Traumatic Seizures and Neuropsychological Functioning after Traumatic Brain Injury. Epilepsy Behav. 16(3):501-506.
Crossref

 

Asleh R, Marsh S, Shilkrut M, Binah O, Guetta J, Lejbkowicz F, Enav B, Shehadeh N, Kanter Y, Lache O, Cohen O, Levy NS, Levy AP. (2003). Genetically determined heterogeneity in hemoglobin scavenging and susceptibility to diabetic cardiovascular disease. Circ. Res. 92(11):1193-200.
Crossref

 

Attilakos A, Papakonstantinou E, Schulpis K, Voudris K, Katsarou E, Mastroyianni S, Garoufi A (2006). Early effect of sodium valproate and carbamazepine monotherapy on homocysteine metabolism in children with epilepsy. Epilepsy Res. 71:229-232.
Crossref

 

Bernard DR, Langlois MR, Delanghe JR, De Buyzere ML (1997). Evolution of haptoglobin concentration in serum during the early phase of acute myocardial infarction. Euro. J. Clin. Chem. Clin. Biochem. 35(2):85-88.
Crossref

 

Conti M, Morand PC, Levillain P, Lemonnier A (1991). Improved Fluorometric. Clin. Chem. 37(7):1273-1275.

 

Eiris JM, Lojo S, Del Rio MC, Novo I, Bravo M, Pavon P, Castro-Gago M (1995). Effects of long-term treatment with antiepileptic drugs on serum lipid levels in children with epilepsy. Neurology 45:1155-1157.
Crossref

 

Fall M, Toure K, Seck LB, Ndiaye M, Diop AG, Ndiaye MM (2015). Profil épidémiologique et prise en charge socioéconomique des patients vivant avec l'épilepsie à Dakar, Sénégal. La Tunisie Médicale. 93(2):101-103.

 

Gogishvili AV, Kavtaradze, VG, Mamaladze GT, Arutiunova MS, Takadze GSH (1985). Haptoglobin phenotype distribution in patients at high risk of developing myocardial infarct. Kardiologiia 25(2):55-58.

 

Guetta J, Strauss M, Levy NS, Fahoum L, Levy AP (2007). Haptoglobin genotype modulates the balance of Th1/Th2 cytokines produced by macrophages exposed to free haemoglobin. Atherosclerosis 191(1):48-53.
Crossref

 

Hamed SA, Hamed EA, Hamdy R, Nabeshima T (2007). Vascular risk factors and oxidative stress as independent predictors of asymptomatic atherosclerosis in adult patients with epilepsy. Epilepsy Res. 74:183-192.
Crossref

 

Hassan A, Hunt BJ, O'Sullivan M, Bell R, D'Souza R, Jeffery S, Bamford JM, Markus HS (2004). Homocysteine is a risk factor for cerebral small vessel disease, acting via endothelial dysfunction. Brain 127:212-219.
Crossref

 

Hauser WA, Annegers JF, Kurland LT (1991). Prevalence of epilepsy in Rochester, Minnesota: 1940–1980. Epilepsia 32:429-445.
Crossref

 

Ilzecka J (1996). The biological role of haptoglobin and behaviour of this protein in different diseases, with special attention paid to brain stroke. Ann. Univ. Mariae Curie Sklodowska Med. 51:115-121.

 

Isnard J, Guenot M, Ostrowsky K, Sindou M, Mauguiere F (2000). The role of the insular cortex in temporal lobe epilepsy. Ann. Neurol. 48(4):614-623.
Crossref

 

Isojärvi JI, Pakarinen AJ, Myllylä VV (1993). Serum lipid levels during carbamazepine medication. A prospective study. Arch. Neurol. 50:590-593.
Crossref

 

Kullo IJ, Ballantyne CM (2005). Conditional risk factors for atherosclerosis. Mayo Clin. Proc. 80:219-230.
Crossref

 

Langlois MR., Delanghe JR (1996). Biological and clinical significance of haptoglobin polymorphism in humans. Clin. Chem. 42(10):1589-1600.

 

Levy AP, Hochberg I, Jablonski K, Resnick HE, Lee ET, Best L, Howard BV (2002). Haptoglobin phenotype is an independent risk factor for cardiovascular disease in individuals with diabetes: The Strong Heart Study. J. Am. Coll. Cardiol. 40(11):1984-1990.
Crossref

 

Levy AP, Roguin A, Hochberg I, Herer P, Marsh S, Nakhoul FM, Skorecki K (2000). Haptoglobin phenotype and vascular complications in patients with diabetes. N. Engl. J. Med. 343:969-670.
Crossref

 

MacKellar M, Vigerust DJ (2016). Role of Haptoglobin in Health and Disease: A Focus on Diabetes. Clin. Diabetes 34:148-157.
Crossref

 

McCorry D, Chadwick D, Marson A (2004). Current drug treatment of epilepsy in adults. Lancet Neurol. 3:729-735.
Crossref

 

Melamed-Frank M, Lache O, Enav BI, Szafranek T, Levy NS, Ricklis RM (2001). Structure-function analysis of the antioxidant properties of haptoglobin. Blood 98(13):3693-3698.
Crossref

 

Moatti N. (2003). Athérosclérose : concepts actuels. In: Delattre J, Durand G, Jardillier JC. Biochimie pathologique: 83-90. Flammarion Médecine-Sciences, Paris, 2003.

 

N'diaye S (2010). Les hallucinations dans les épilepsies partielles à propos de 31 cas Mémoire du CES de Neurologie. Université Cheikh Anta Diop, Dakar, n°331.

 

Nakhoul FM, Zoabi R, Kanter Y, Zoabi M, Skorecki K, Hochberg I, Leibu R, Miller B, Levy AP (2001). Haptoglobin phenotype and diabetic nephropathy. Diabetologia 44(5):602-604.
Crossref

 

Ngoungou EB, Quet F, Dubreuil CM, Marin B, Houinato D, Nubukpo P, Dalmay F, Millogo A, Nsengiyumva G, Kouna-Ndouongo P, Diagana M, Ratsimbazafy V, Druet-Cabanac M, Preux PM (2006). Épidémiologie de l'épilepsie en Afrique subsaharienne : une revue de la littérature. Epilepsies 18(1):25-40.

 

Nikolaos T, Stylianos G, Chryssoula N, Irini P, Christos M, Dimitrios T, Konstantinos P, Antonis T (2004). The effect of long-term antiepileptic treatment on serum cholesterol (TC, HDL, LDL) and triglyceride levels in adult epileptic patients on monotherapy. Med. Sci. Monit. 10:MT50-MT52.

 

Osuntokun BO, Adeuja AO, Nottidge VA (1987). Prevalence of the epilepsies in Nigerian Africans: a community-based study. Epilepsia 28:272-279.
Crossref

 

Osuntokun BO, Schoenberg BS, Nottidge VA, Adeuja A, Kale O, Adeyefa A, Bademosi O, Olumide A, Oyediran ABO, Pearson CA, Bolis CL (1982). Research protocol for measuring the prevalence of neurologic disorders in developing countries, results of pilot study in Nigeria. Neuroepidemiology 1(3):143-153.
Crossref

 

Panter SS, Sadrzadeh SM, Hallaway PE, Haines J, Anderson VE, Eaton JW (1984). Hypohaptoglobinemia: a possible predisposition to epilepsy. Trans. Assoc. Am. Physicians 97:56-62.

 

Raymond S (1962). A convenient apparatus for vertical gel electrophoresis. Clin Chem. 8:455-470.

 

Rwiza HT, Kilonzo GP, Haule J (1992). Prevalence and incidence of epilepsy in Ulanga, a rural Tanzanian District: A community-based study. Epilepsia 33:1051-1056.
Crossref

 

Saccucci P, Verdecchia M, Piciullo A, Bottini N, Rizzo R, Gloria-Bottini F, Lucarelli P, Curatolo P (2004). Convulsive disorder and genetic polymorphism. Association of idiopathic generalized epilepsy with haptoglobin polymorphism. Neurogenetics 5:245-248.
Crossref

 

Sadrzadeh SM, Saffari Y, Bozorgmehr J (2004). Haptoglobin phenotypes in epilepsy. Clin. Chem. 50:1095-1097.
Crossref

 

Schwaninger M, Ringleb P, Winter R, Kohl B, Fiehn W, Rieser PA, Walter-Sack I (1999). Elevated plasma concentrations of homocysteine in antiepileptic drug treatment. Epilepsia 40:345-350.
Crossref

 

Stocker R, Keaney JF Jr. (2004). Role of oxidative modifications in atherosclerosis. Physiol. Rev. 84:1381-1478.
Crossref

 

Tan TY, Lu CH, Chuang HY, Lin TK, Liou CW, Chang Wn, Chuang YC (2009). Long-term antiepileptic drug therapy contributes to the acceleration of atherosclerosis. Epilepsia 50(6):1579-1586.
Crossref

 

Tekle-Haimanot R, Forsgren L, Ekstedt J. (1997). Incidence of epilepsy in rural central Ethiopia. Epilepsia 38:541-546.
Crossref

 

Temple ME, Luzier AB, Kazierad DJ (2000). Homocysteine as a risk factor for atherosclerosis. Ann. Pharmacother. 34:57-65.
Crossref

 

Tseng CF, Lin CC, Huang HY, Liu HC, Mao SJ (2004). Antioxidant role of human haptoglobin. Proteomics 4:2221-2228.
Crossref

 

Tyagi N, Ovechkin AV, Lominadze D, Moshal KS, Tyagi SC (2006). Mitochondrial mechanism of microvascular endothelial cells apoptosis in hyperhomocysteinemia. J. Cell. Biochem. 98:1150-1162.
Crossref

 

Yagi K (1976). A simple fluorometric assay for lipoperoxide in blood plasma. Biochem. Med. 15:212-216.
Crossref

 


APA GUEYE, P. M., DJITE, M., NDOUR, E. M., GUEYE-TALL, F., BARRY, N. O. K., SARR, A., NDIAYE DIALLO, R., LOPEZ SALL, P., CISSE, A., & DIOP, P. A. (2017). Haptoglobin polymorphism and cardiovascular risk factors in followed epileptic patients at Fann National University Hospital. African Journal of Biochemistry Research , 11(8), 43-48.
Chicago Papa Madièye GUEYE, Moustapha DJITE, El Hadji Malick NDOUR, Fatou GUEYE-TALL, N&en&e Oumou Kesso BARRY, Aïssatou SARR, Rokhaya NDIAYE DIALLO, Philomène LOPEZ SALL, Aynina CISSE and Pape Amadou DIOP. "Haptoglobin polymorphism and cardiovascular risk factors in followed epileptic patients at Fann National University Hospital." African Journal of Biochemistry Research 11, no. 8 (2017): 43-48.
MLA Papa Madiegrave;ye GUEYE, et al. "Haptoglobin polymorphism and cardiovascular risk factors in followed epileptic patients at Fann National University Hospital." African Journal of Biochemistry Research 11.8 (2017): 43-48.
   
DOI 10.5897/AJBR2017.0939
URL http://academicjournals.org/journal/AJBR/article-abstract/85B096E65668

Subscription Form